Patents by Inventor Cedric Francois

Cedric Francois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12261503
    Abstract: A motor comprises a housing having a cylindrical recess for receiving and centering a cylindrical wound stator. The stator has an overmolded electrical connection assembly with connecting tabs extending transversely. The stator, being equipped with the electrical connection assembly, is overmolded with an electrically insulating resin. The housing has a lateral protrusion for connecting with a complementary connection assembly. The housing has, in its rear portion, a first angular wedging means complementary to a second angular wedging means provided at the rear portion of the overmolded electrical connection assembly.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: March 25, 2025
    Assignee: Sonceboz Mechatronics Boncourt SA
    Inventors: Cédric Mellere, Jean-François Place
  • Publication number: 20250096586
    Abstract: An adaptive tracking clamp acting as an extra regulation loop that limits excursions, such as at a transition from one regulation loop to another. The adaptive tracking clamp is dynamically positioned relative to the level of the regulation loop in control. In case of fast transient events, the loop that is initially in control will quickly raise the output demand but in a first time get limited by the adaptive tracking clamp level; in a second time the adaptive tracking clamp algorithm incrementally increases the output demand until handing off control to the other regulation loop.
    Type: Application
    Filed: August 6, 2024
    Publication date: March 20, 2025
    Inventors: Olivier Stéphane Simon Depuits, Bruno Zurlinden, Thierry Jean-Claude Robert Tellier, Anthony Gabriel Lucien Arzur, Cedric Francois Raphael Blanc
  • Publication number: 20250040884
    Abstract: A breath monitoring apparatus is provided herein, the apparatus having one or more respiration sensors configured to output a respiration signal indicative of a respiration parameter of a user during a respiration activity: a feedback indicator configured to provide a sensory output to a user relating to the respiration signal; and a controller communicatively coupled to the respiration sensor and the feedback indicator, and configured to: provide instructions correlating to a desired breathing activity to the user during the respiration activity: receive and analyze the respiration signal output by the respiration sensor to determine a biofeedback score based on the respiration signal, wherein the biofeedback score is indicative of the user's respiration signal compared to the desired breathing pattern; and provide feedback to the user through the feedback indicator based on the biofeedback score, wherein the breath monitoring apparatus is configured to be wearable by the user.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 6, 2025
    Applicants: Breezee, Inc., Liberate Medical LLC
    Inventors: Cedric Francois, Angus McLachlan
  • Publication number: 20250000936
    Abstract: Methods and compositions for treatment of geographic atrophy are described.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 2, 2025
    Inventors: Cedric Francois, Pascal Deschatelets, Federico Grossi
  • Publication number: 20240285783
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: November 2, 2023
    Publication date: August 29, 2024
    Applicant: Apellis Pharmaceuticals, Inc.
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Publication number: 20240285725
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: December 21, 2023
    Publication date: August 29, 2024
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois
  • Publication number: 20240191673
    Abstract: A guide assembly for an aircraft propulsion unit, the guide assembly having a first element and at least one guide element attached to the first element. The guide element includes a bottom wall, two lateral walls connected together by the bottom wall, and an opening defined between the bottom wall and the lateral walls. The opening is configured to receive at least partly a second element configured to move relative to the guide element. The guide element can further include at least one pair of gripping tongues cooperating with holding members of the first element to retain the guide element on the first element.
    Type: Application
    Filed: September 20, 2023
    Publication date: June 13, 2024
    Applicant: SAFRAN NACELLES
    Inventors: Pierre PELLERIN, Cedric François Pierre RENAULT
  • Publication number: 20240115655
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: February 28, 2023
    Publication date: April 11, 2024
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Publication number: 20240076317
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
    Type: Application
    Filed: April 11, 2023
    Publication date: March 7, 2024
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 11903994
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 20, 2024
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois
  • Patent number: 11885281
    Abstract: An aeronautical thrust reverser including a sliding cowl, shutter flaps and deflection cascades. The reverser includes, for each flap, a return member hinged to the sliding cowl, to a driving connecting rod itself hinged to a front frame of the reverser, and to a return connecting rod itself hinged to the flap, the latter being moreover hinged by its rear end to the sliding cowl. The return member, the driving connecting rod and the return connecting rod form an actuation system capable of opening the secondary flow duct in a direct thrust configuration.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 30, 2024
    Assignee: SAFRAN NACELLES
    Inventors: Josse Plaquin, Cedric François Pierre Renault
  • Patent number: 11844841
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: December 19, 2023
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Patent number: 11712460
    Abstract: In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: August 1, 2023
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 11661441
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: May 30, 2023
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Publication number: 20230091471
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: February 16, 2022
    Publication date: March 23, 2023
    Inventors: Cedric Francois, Pascal Deschatelets
  • Publication number: 20230076527
    Abstract: Methods and compositions for treatment of paroxysmal nocturnal hemoglobinuria are described. In some aspects, the disclosure features a method of treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising subcuta-neously administering to the subject pegcetacoplan.
    Type: Application
    Filed: January 7, 2021
    Publication date: March 9, 2023
    Inventors: Pascal Deschatelets, Cedric Francois, Federico Grossi, Sharon Morriss, Elizabeth F. Tan
  • Publication number: 20230075121
    Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder. e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.
    Type: Application
    Filed: June 29, 2022
    Publication date: March 9, 2023
    Inventors: Cedric Francois, Pascal Deschatelets, Monica Gerber
  • Publication number: 20230072111
    Abstract: The present invention provides, among other things, apparatus and methods of use for treating a subject in need of assistance with breathing. In some embodiments the subject suffers from airflow obstruction. In some embodiments, the subject suffers from chronic obstructive pulmonary disease.
    Type: Application
    Filed: November 11, 2022
    Publication date: March 9, 2023
    Applicant: Apellis Holdings, LLC
    Inventors: Cedric Francois, Angus McLachlan
  • Publication number: 20230009757
    Abstract: In some aspects, the present invention provides certain combination therapies comprising compstatin analogs.
    Type: Application
    Filed: April 12, 2022
    Publication date: January 12, 2023
    Applicants: Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc.
    Inventor: Cedric Francois
  • Patent number: 11529283
    Abstract: The present invention provides, among other things, apparatus and methods of use for treating a subject in need of assistance with breathing. In some embodiments the subject suffers from airflow obstruction. In some embodiments, the subject suffers from chronic obstructive pulmonary disease.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: December 20, 2022
    Assignee: APELLIS HOLDINGS, LLC
    Inventors: Cedric Francois, Angus McLachlan